株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

潰瘍性大腸炎の世界市場:2016〜2020年

Global Ulcerative Colitis Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 357712
出版日 ページ情報 英文 67 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
潰瘍性大腸炎の世界市場:2016〜2020年 Global Ulcerative Colitis Market 2016-2020
出版日: 2016年05月02日 ページ情報: 英文 67 Pages
概要

潰瘍性大腸炎は、大腸や直腸の炎症性腸疾患の一種で、大腸や直腸の最深部に炎症や潰瘍が形成されます。腹部痙攣、下痢、直腸出血などが一般的な症状としてみられます。世界の潰瘍性大腸炎市場は、2016〜2020年にかけ、CAGR6.6%で拡大すると予測されています。

当レポートでは、世界の潰瘍性大腸炎市場の現状と2020年までの成長見通し、市場の動向と課題、地域別動向、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 市場調査方法

第4章 イントロダクション

第5章 疾患概要

  • 疾患の理解
  • 病因
  • 疫学
  • 症状
  • 診断と検査
  • 治療
  • 予後
  • 経済的負担
  • 償還シナリオ

第6章 パイプライン分析

第7章 市況

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第8章 分子タイプ別市場セグメンテーション

  • 生物製剤
  • 小分子
  • 潰瘍性大腸炎薬剤市場における生物製剤セグメント
  • 潰瘍性大腸炎薬剤市場における小分子セグメント

第9章 剤形別市場セグメンテーション

  • 固形
  • 液体

第10章 投与ルート別市場セグメンテーション

  • 経口
  • 非経口

第11章 地域別セグメンテーション

  • 地域別市場
  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第12章 市場促進因子

  • 患者支援プログラムの増加
  • 高いアンメットニーズ
  • パイプライン候補の一次認可

第13章 促進因子の影響

第14章 市場の課題

  • 薬剤コストの高さ
  • 特許の執行
  • 薬剤の副作用
  • 不明な病因

第15章 促進因子と課題の影響

第16章 市場動向

第17章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析:2015年
  • AbbVie
  • Janssen Biotech
  • Merck
  • 武田製薬工業株式会社
  • その他の注目すべきベンダー

第18章 付録

第19章 Technavioについて

図表

図表
  • Exhibit 01: Product offerings
  • Exhibit 02: Causes of ulcerative colitis
  • Exhibit 03: Symptoms of ulcerative colitis
  • Exhibit 04: Diagnostic approach for ulcerative colitis
  • Exhibit 05: Treatment options for ulcerative colitis
  • Exhibit 06: Treatment guidelines of ulcerative colitis based on severity
  • Exhibit 07: Surgical procedures to treat ulcerative colitis
  • Exhibit 08: Global ulcerative colitis drugs market: Pipeline portfolio
  • Exhibit 09: Global ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 10: Snapshot of global ulcerative colitis drugs market
  • Exhibit 11: Five forces analysis
  • Exhibit 12: Global ulcerative colitis drugs market by molecule type
  • Exhibit 13: Global ulcerative colitis drugs market by molecule type 2015
  • Exhibit 14: Biologics segment in ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 15: Small molecules segment in ulcerative colitis drugs market 2015-2020 ($ billions)
  • Exhibit 16: Global ulcerative colitis drugs market by dosage form
  • Exhibit 17: Global ulcerative colitis drugs market by route of administration
  • Exhibit 18: Global ulcerative colitis drugs market segment by geography 2015
  • Exhibit 19: Ulcerative colitis drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 20: Ulcerative colitis drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 21: Ulcerative colitis drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 22: Ulcerative colitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 23: Impact of drivers
  • Exhibit 24: Impact of drivers and challenges
  • Exhibit 25: Global ulcerative colitis drugs market share analysis 2015
  • Exhibit 26: YoY revenue comparison of top drugs for ulcerative colitis 2011-2014 ($ millions)
  • Exhibit 27: AbbVie: Product segmentation by revenue 2014
  • Exhibit 28: AbbVie: Product segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 29: AbbVie: Geographical segmentation by revenue 2014
  • Exhibit 30: AbbVie: YoY growth and revenue of Humira 2012-2014 ($ billions)
  • Exhibit 31: AbbVie: Key takeaways
  • Exhibit 32: Janssen Biotech: YoY growth and revenue of Remicade 2012-2014 ($ millions)
  • Exhibit 33: Janssen Biotech: YoY growth and revenue of Simponi/Simponi ARIA 2012-2014 ($ millions)
  • Exhibit 34: Janssen Biotech: Key takeaways
  • Exhibit 35: Merck: Business segmentation by revenue 2014
  • Exhibit 36: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 37: Merck: Geographical segmentation by revenue 2014
  • Exhibit 38: Merck: YoY growth and revenue of Remicade 2012-2014 ($ millions)
  • Exhibit 39: Merck: YoY growth and revenue of Simponi 2012-2014 ($ millions)
  • Exhibit 40: Merck: Key takeaways
  • Exhibit 41: Takeda Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 42: Takeda Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2014
  • Exhibit 44: Takeda Pharmaceuticals: Key takeaways
目次
Product Code: IRTNTR8159

About Ulcerative Colitis

Ulcerative colitis is a type of inflammatory bowel disease (IBD) that affects the colon and rectum. Inflammation and ulcers are formed in the innermost lining of the colon and rectum, resulting in the production of pus and mucous. Based on the extent of inflammation and the location, ulcerative colitis can be of different types: ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. Abdominal cramps, diarrhea, and rectal bleeding are among the common symptoms observed in individuals with the disease. Medications such as 5-aminosalicylates, steroids, purine analogs, immunomodulators, and biologics are used to treat the disease.

Technavio's analysts forecast the global ulcerative colitis market to grow at a CAGR of 6.6% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global ulcerative colitis market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used to treat ulcerative colitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Ulcerative Colitis Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Ajinomoto Pharmaceuticals
  • Amgen
  • Arena Pharmaceuticals
  • AstraZeneca
  • Astellas Pharma
  • Avaxia Biologics
  • BioLineRx
  • Celgene
  • Cosmo Pharmaceuticals
  • Eisai
  • Ferring Pharmaceuticals
  • Galapagos
  • Genentech
  • Gilead Sciences
  • GlaxoSmithKline
  • Hutchison Medi Pharma
  • Immune Pharmaceuticals
  • InDex Pharmaceuticals
  • Kaken Pharmaceutical
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Lipid Therapeutics
  • Meda
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Morphotek
  • Nestle
  • Pfizer
  • Procter & Gamble
  • Qu Biologics
  • Receptos
  • Salix Pharmaceuticals
  • Shield Therapeutics
  • Shire Pharmaceuticals
  • Sterna Biologicals
  • Tillotts Pharma
  • TopiVert
  • UCB
  • Zeria Pharmaceutical

Market driver

  • Increase in patient assistance programs
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries
  • For a full, detailed list, view our report

Market trend

  • Rising use of biologics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Etiology
  • Epidemiology
  • Symptoms
  • Diagnosis and testing
  • Treatment
  • Prognosis
  • Economic burden
  • Reimbursement scenario

PART 06: Pipeline analysis

  • Z-206
  • MD-0901
  • TP05
  • Stelara
  • Etrolizumab
  • Xeljanz
  • HMPL-004
  • Kappaproct
  • AJG511
  • AJM300

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by molecule type

  • Biologics
  • Small molecules
  • Biologics segment in ulcerative colitis drugs market
  • Small molecules segment in ulcerative colitis drugs market

PART 09: Market segmentation by dosage form

  • Solid
  • Liquid

PART 10: Market segmentation by route of administration

  • Oral
  • Parenteral

PART 11: Geographical segmentation

  • Global ulcerative colitis drugs market by geography 2015-2020
  • Ulcerative colitis drugs market in Americas
  • Ulcerative colitis drugs market in EMEA
  • Ulcerative colitis drugs market in APAC

PART 12: Market drivers

  • Increase in patient assistance programs
  • High unmet needs
  • Tentative approval of candidates in pipeline

PART 13: Impact of drivers

PART 14: Market challenges

  • High cost of drugs
  • Patent expiries
  • Adverse effects of drugs
  • Unknown disease etiology

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Growing public awareness
  • Rising use of biologics
  • Emergence of biosimilars
  • Strategic alliances

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • AbbVie
  • Janssen Biotech
  • Merck
  • Takeda Pharmaceuticals
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

Back to Top